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Sir,
We are grateful to Clark for raising her concerns about our
article on using high-intensity focused ultrasound (HIFU) to treat
localised prostate cancer and the subsequent press interest within
the UK (Ahmed et al, 2009). Outcomes are difficult to define in
minimally invasive therapies of prostate cancer and there is no
consensus about what is a successful outcome. What is certain is
that prostate cancer is an over-diagnosed and over-treated disease
for which treatments that can achieve low rates of incontinence
and impotence are paramount. Through this independent,
anonymous peer-reviewed paper, we have attempted to present
our results in an open manner, with all data presented and
summarised in such a way that has so far evaded this area of
research. Incontinence is truly very low after HIFU. We thank
Clarke for highlighting the weaknesses in the potency data. Our
denominator, on which we have based the potency rates, is within
the paper for all to evaluate. We have made no attempt to disguise
this, although it is extremely difficult to fit all caveats and data into
a short abstract. We are extremely grateful to the British Journal of
Cancer for making available the full paper online for a period of
time after publication without charge.
It is difficult to control press articles about research outcome.
Reporters and editors of newspapers are interested in sound bites
and headlines. The press release was written, edited and approved
by Cancer Research UK and ourselves, as well as approved by the
communication departments of a number of organisations
involved in this piece of work. In addition, independent comments
were made by the Prostate Cancer Charity and Cancer Research
UK. They and ourselves were keen to emphasise the preliminary
nature of these results and manage the expectations. In fact, all
press coverage had quoted statements to this effect. Further, the
NHS website covered the paper in detail and stated that ‘Headlines
like ‘‘Prostate cancer treatment more successful than surgery’’ are
not accurate at present’ (http://www.nhs.uk/news/2009/07july/
pages/ultrasoundforprostatecancer.aspx).
However, we must not forget that everyday research is reported
upon by press and media. This coverage is important as it
generates interest, keeps the population informed, builds recruit-
ment into prospective clinical trials that aim to answer the difficult
questions of the day, and allows the public to gain an insight into
the research work of the National Health Service and universities
within the UK.
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